Jarushka Naidoo, MD, John Hopkins University, Baltimore, MD, talks on unanswered questions regarding the use of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC), including the uncertain role of immunotherapy (IO) in the early stages of NSCLC and whether there are biomarkers beyond PD-L1 for selecting patients for IO, as well as biomarkers for predicting toxicity. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.